Autonomous colony formation is a frequent event in erythroleukemia. In 13 cases of early erythroid leukemias, we investigated whether erythropoietin (Epo) autocrine stimulation was responsible for the growth factor autonomy. Epo transcripts were detected by Northern blotting in cells from one patient. These cells also expressed an Epo receptor (1,000 receptors per cell) with a 420-pM affinity and Epo was detected in the supernatant of cultured cells. In 8 of the 13 cases, Epo transcripts were revealed by the polymerase chain reaction ranng from 0.5 to 500 copies per cell. In situ hybridization proved that these Epo transcripts were present in the blast cells. No Epo gene abnormalities were detected by Southern blotting. In two cases, leukemic cells were grown in the presence of Epo-neutralizing antibodies or Epo antisense oligomers. In one case, the antibody significantly reduced autonomous growth. In contrast, the antibody had no effect in the second case in which blast cells transcribed the Epo gene at a low level. However, Epo antisense oligomers partially inhibited autonomous growth. This inhibition was reversed by addition of exogenous Epo. Overall, these results suggest that an extracellular or intracellular autocrine Epo stimulation occurs in some cases of erythroid malignancies. (J. Clin. Invest. 1991. 88:789-797.)
Introduction
Human erythroid malignant pathologies are of two types. The first, polycythemia vera, is a chronic disease that associates an erythroid hyperplasia with a normal erythroid differentiation and involves a pluripotent stem cell (1) . The second consists of true erythroid leukemias. However, these leukemias are quite heterogenous at the cellular level and arise from blockages at different stages of erythroid differentiation. Erythroleukemia (M6 in the French American British classification) is characterized by marked erythroid hyperplasia with major erythroid morphological defects, together with the presence ofcirculating erythroblasts and marrow blast cells (2) . Recently, we and others (3) (4) (5) (6) (7) have identified a new type of erythroleukemia in which leukemic cells are blocked at an early stage of erythroid differentiation and are not morphologically identifiable. In the absence ofdifferentiation markers, these forms are classified as either undifferentiated, lymphoblastic, or even monoblastic leukemias and have been termed cryptic erythroleukemia (4) or early erythroid leukemia (3) .
These early erythroid leukemias can be subclassified into two types (3) . One corresponds to cells blocked at a stage of differentiation identical to that of CFU-erythroid. The main differentiation markers expressed are carbonic anhydrase 1 (CAl1)', cluster ofdifferentiation 36 (CD36), glycophorin C (3), transferrin receptors, and often A, B, and H blood groups. In the second, the erythroid leukemic cells correspond to proerythroblasts or pre-proerythroblasts (8) , with the presence of glycophorin A (GPA) but rarely of hemoglobin (3) . These erythroid leukemic cells have specific ultrastructural characteristics which include the presence of ferritin aggregates and peculiar 0 granules (7, 9) . While differing in their phenotype, all these erythroid malignancies exhibit some degree of factor-independent growth. In polycythemia vera, spontaneous erythroid colony formation (10-12) may be related either to true erythropoietin (Epo) independence (13) or to Epo hypersensitivity (14, 15) . We have recently shown that most cases ofearly erythroid leukemia are also Epo independent, since spontaneous leukemic colony formation occurs in serum-free conditions, even in limiting-dilution experiments (16) . However, as in polycythemia vera, Epo increases the plating efficiency of the leukemic cells. Similar results have been described in M6 leukemia (17) .
It appears therefore that the bypass ofexogenous Epo could be a mechanism involved in human erythroid malignancies. A similar phenomenon has been observed in a murine erythroleukemia. Recent studies have shown that the Friend spleen focus-forming virus induces Epo independence through the specific interaction of glycoprotein 55 (Gp55), a viral envelope protein, with the Epo receptor which may thereby trigger cell growth (18) (19) (20) .
In this study, we investigated whether autocrine stimulation by Epo could explain the autonomous growth of human erythroid leukemic cells. In the majority of cases, leukemic erythroid cells were found to synthesize Epo mRNA and true autocrine stimulation by Epo was observed in one case.
Methods
Patients. 13 patients with early erythroid leukemia were studied (Table   I ). Seven of these subjects have already been studied in detail (patients 1. Abbreviations used in this paper: CA 1, carbonic anhydrase 1; CD36, cluster of differentiation 36; Epo, erythropoietin; Gp55, glycoprotein 55; GPA, glycophorin A; PCR, polymerase chain reaction; rh, recombinant human. (16) . The diagnosis ofearly erythroid leukemia was ascertained when differentiation markers showed the presence of CAl and CD36 and, occasionally, GPA on blast cells and ferritin aggregates and 0 granules were revealed by ultrastructural studies (3, 9) . The percentage of blast cells was > 90% after Ficoll-metrizoate gradient separation of blood or marrow samples. There were three cases of erythroleukemic blast transformation of chronic myeloid leukemia, three cases of leukemias in patients with constitutive trisomy 21, and seven cases of de novo leukemia. This study was performed either on fresh or frozen blood or marrow cells from patients since we were unable to derive continuous leukemic cell lines from these samples.
Semi-solid culture procedures. Cultures were maintained in serumfree medium using a previously described technique (21) applied to human cells (16) . Briefly, the medium contained 1.5% deionized serum albumin (Cohn fraction V; Sigma Chemical Co., St. Louis, MO), ironsaturated human transferrin (300 .g/ml; Sigma), calcium chloride (28 ,gg/ml), a mixture of sonicated lipids, 7.5 X 10-' M a-thioglycerol, 100 ng/ml insulin, and 0.8% 4,000 chemically pure methylcellulose in Iscove's modified Dulbecco's medium. The lipid mixture was obtained by sonicating 7.8 mg cholesterol, 6.14 mg oleic acid, and 7.4 mg dipalmitoyl lecithin (all obtained from Sigma) in 10 ml ofIscove's modified Dulbecco's medium (without sodium bicarbonate) containing 1% serum albumin. 20 ul of this mixture was used per milliliter of culture.
Cultures were performed in triplicate in l-ml vol in petri dishes (Corning Glass Inc., Corning, NY) with cell concentrations ranging from 5 X I03 to 25 x I03 cells/ml. Cultures were incubated for 7 (24) . The digests were size fractionated by means ofelectrophoresis in 1% agarose gels, and the gels were blotted to Hybond C-Extra membranes. The blots were hybridized, as previously described, with a32P-labeled Epo cDNA probe (23) . Blots were washed four times in 2x SSC/0. 1% SDS at room temperature and three times in 0.1 X SSC/0. 1% SDS at 56°C. Autoradiography was performed using Kodak X-OMAT AR film (Kodak Pathef).
Polymerase chain reaction (PCR These amplification products included in the same fragment the previous amplified regions ofthe Epo mRNA and coded for 150 amino acid on 173 of the Epo molecule. cDNA was synthesized with 300 ng (HepG2) or 2 ug (patients) of total denatured RNA and 100 ng of random hexadeoxynucleotide primers (Pharmacia, Saint-Quentin-enYvelines, France). Oligonucleotides used for the 451-bp RNA fragment amplification were the sense strand GCCCCACCACGCCT-CATCTGT (nt 82 to nt 102), and the antisense strand CCCGGA-GGAAATTGGAGTAGA (nt 532 to nt 512). For the 523-bp RNA fragment the sense strand was CACGAATGTCCTGCCTGGCTG (nt 10 to nt 30), and the previous antisense strand. The internal oligonucleotide used to blot the amplification product was the first of the two previously described internal oligonucleotides (see above).
Quantitative PCR. Patients 2, 3, 4, 10, and 13 were studied for the quantitative PCR reaction (28) . A 189-base RNA fragment was constructed; its two extremities contained complementary sequences to the two oligomers used for the amplification of the Epo transcript between the second and third exon. After amplification, its size (189 bp) is different from the normal amplified Epo transcript (155 bp) and allows a competitive PCR reaction. This synthetic RNA (106 molecules) was mixed with increasing amounts of the test RNA. The PCR procedure was performed as described above; one-tenth ofthe amplification product was electrophoresed in an acrylamide gel that was stained with ethidium bromide and visualized under UV light. When the intensity of the two bands (155 bp and 189 bp) was identical it was considered that the RNA sample contained Io6 Epo transcript copies.
In situ hybridization. Several molecular probes were used. The Epo probe used for in situ hybridization studies was a 720-bp insert of human Epo cDNA cloned into the pBS M 13 plasmid (Stratagene Inc., La Jolla, CA). This probe covered the two RNA fragments in 5' and 3' which were studied by PCR. As positive and negative controls, we used a murine f3-actin cDNA cloned into a transcription vector. As a negative control we used a 1.37-kb A phage DNA fragment cloned into a pGEM vector (Promega Biotec). Run-offtranscripts ofappropriate linearized plasmids were synthesized using T7, SP6, or T3 RNA polymerase in a reaction mixture containing 60 MCi [a35S UTP (1, 200 Ci/ mmol; Amersham) according to the manufacturer's instructions (Promega Biotec), except that unlabeled UTP was omitted to achieve synthesis of the RNA probe with a sp act of I09 cpm/,gg. The fragment length of the RNA probes was adjusted to an average of -100-150 bases by limited alkaline hydrolysis (29) . The RNA probes were of similar specific activity and size (determined by gel electrophoresis under denaturing conditions). Fixation, hybridization, and stringent washes were carried out as previously described (29) (30) (31) , with some modifications. The cells were cytocentrifuged and immediately fixed in 4% paraformaldehyde in PBS, pH 7.4, for 3 min at room temperature. Preparations were then transferred to 70% ethanol and stored at 4VC until use. At this point, negative control slides were treated with 100 Atg/ml RNase A (Sigma) in 2 x SSC for 2 h at 370C. The slides were postfixed in 2% paraformaldehyde/1% glutaraldehyde in PBS for 7 min, washed in PBS, acetylated, washed in PBS, dehydrated in ethanol, and air dried. RNA probes were ethanol precipitated with yeast tRNA and salmon sperm DNA and washed with 70% ethanol. The dried pellets were resuspended in the hybridization buffer to give final concentrations of 50% deionized formamide, 0.3 M NaCl, 20 mM Tris-HCI (pH 8), 0.5 mM EDTA, lX Denhardt's solution, 10No dextran sulfate, 20 mM dithiothreitol, 500 Mg/ml yeast tRNA, 1 mg/ml salmon sperm DNA, and 108 cpm/ml of the RNA probe. The hybridization mixture was denatured and applied to the slides. Hybridization was performed at 50'C for 20 h in a humidified chamber. The slides were successively washed at 540C three times in 2 X SSC/dithiothreitol (10 mM), three times in the same buffer plus 50% formamide, and three times in 2 x SSC/dithiothreitol (1 mM), followed by RNase digestion. After a second series ofwashings, the slides were successively rinsed in decreasing concentrations of SSC with 1 mM dithiothreitol, dehydrated in ethanol, air dried, and coated with NTB2 emulsion (International Biotechnologies, Inc., A Kodak Co., New Haven, CT) forautoradiography. After 15 d of exposure, the slides were developed in Dektol (Kodak Pathe), fixed in Unifix (Kodak Pathe), and stained with MayGrunwald Giemsa. The number of silver grain per cell was counted and the cells were categorized according to the number of silver grain. More than 200 cells were counted per slide per experiment.
Cells from two patients were subjected to in situ hybridization in at least three separate experiments. In addition to the positive (,B actin) and negative (X phage) control probes and ribonuclease-pretreated slides, two positive controls (an Epo cDNA transfected CHO cell line and the HepG2 cell line) for the Epo probe were included. Epo receptor characterization. The methods used for binding studies have been fully described elsewhere (32, 33) . With the exception of one patient, the presence of Epo receptors was ascertained by binding of '25I Epo to 2 x 106 cells. Nonspecific binding was measured using the same method except that a 100-fold excess of unlabeled Epo was added to the '25I Epo. A Scatchard analysis was performed in one case. Briefly, highly purified rhEpo was iodinated to a sp act of 750 Ci/mmol using the iodogen method. Binding (2 h at 37°C) was initiated by the addition of 1.5 X 106 cells in 100 Ml of Eagle's MEM containing 10% FCS and 0.02% sodium azide and various concentrations of labeled Epo in the presence or absence of excess (at least lOOX) unlabeled Epo. Cells were then washed three times with ice-cold PBS and cell-associated radioactivity was measured by y counting. Specifically bound radioactivity was calculated by subtracting the radioactivity associated with cells incubated with an excess of unlabeled Epo (nonspecific radioactivity) from that of cells incubated with labeled Epo only (total radioactivity). Results of equilibrium experiments were analyzed according to Scatchard's method using unweighted least-square linear regression fitting.
Antisense oligonucleotides. Several unmodified 15-base oligonucleotides were made using a DNA synthesizer (Applied Biosystems, Inc., Foster City, CA) and purified either by two ethanol precipitation steps and multiple washes in 80% ethanol, or by migration in a urea/ polyacrylamide gel, followed by electroelution and ethanol precipitation. After evaporation to dryness the oligonucleotides were dissolved in PBS. We used two 1 5-mer Epo antisense oligomers complementary to the first exon (GTGCACCCCCATCTC, nt 12 to nt -3, and CACCCCCATCTCCGC, nt 9 to nt -6). A positive control, a c-myb antisense oligomer(GTGCCGGGGTCTTCGGGC, nt 21 to nt 3) (34), and a negative control, an Epo sense oligomer (GAGATGGGGGTG-CAC nt -3 to nt 12), were used in these experiments.
These oligomers were incubated in serum-free culture medium devoid of methylcellulose for 3 h at 37°C. Methylcellulose was then added and the cells were cultured normally with a final oligomer concentration of 10 MM. In preliminary experiments, oligomer concentrations ranging from I MM to 50 MM in l-ml petri dishes were tested.
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Anti-Epo antibody. A polyclonal antibody against Epo was obtained by immunizing rabbits with rhEpo. IgG was then isolated using protein-A/Sepharose chromatography (Pharmacia, France). 1-20 Al of anti-Epo IgG (3 mg/ml, neutralizing 2-40 U ofEpo) was added to each culture dish. The same amount of IgG from nonimmunized rabbits was used as a control.
Epo radioimmunoassay. Cells were cultured for 2-7 d in serum-free liquid medium at a concentration of 106 cells per ml. The medium was then recovered and concentrated 10-fold by means of ultrafiltration. Epo was detected using a radioimmunoassay, as previously described (35) 
Results
Patients. 13 patients with early erythroid leukemia were studied (Table I) . Their blood or marrow contained > 90% ofblast cells. The in vitro growth characteristics ofleukemic cells from patients 1, 2, 4, 5, 6, 1 1, and 12 have previously been described in detail (16) . Except for four patients, two with Down's syndrome (patients 1 and 6) and patients 7 and 9, blood or marrow cells formed leukemic erythroid colonies when cultured in the presence of Epo or granulocyte macrophage colony-stimulating factor (GM-CSF). Some colonies were atypical and their erythroid nature was ascertained by the presence of CAl and GPA (3, 16) . In 8 ofthe 13 cases, colonies were observed in the absence of added stimuli, the absolute number ofcolonies was increased in the presence of Epo or GM-CSF.
Northern blot and Epo radioimmunoassay. Northern blotting and radioimmunoassay were used to investigate a possible Epo gene transcription and protein secretion by the leukemic cells. As shown in Fig. 1 is a positive control (RNA from HepG2 cells). 0 is a negative control (RNA replaced by water). Total RNA (100 ng) was reverse transcribed with the antisense oligomer (Epo 5') and then submitted to 30 amplification cycles with the pair of oligomers located at the 5' end of the Epo gene. Part (10%) of the amplification product was analyzed by Southern blotting with a specific oligomer. The size of the amplified RNA is 155 bp. In patient 3 the detection of the amplification product required a longer exposure time than for the other patients.
amplified DNA and RNA were 412 bp and 155 bp for the 5' set of primers, and 286 bp and 152 bp for 3' set ofprimers, respectively. After agarose gel electrophoresis, the amplification products were hybridized with specific oligonucleotide probes.
As in the Northern blot analysis, Epo transcripts were detected in cells from patient 2 by means of PCR analysis using both sets of primers (Figs. 2 and 3) . Moreover, Epo transcripts were also detected in samples from the seven other patients (3, 4, 9, 10, 11, 12, and 13) (Fig. 2) which were negative by Northern analysis. Reproducible quantitative differences in the amount of Epo transcripts were observed between the various patients' samples, and in patients 3, 10, and 13, levels were at the threshold ofdetection. Results with the two pairs ofprimers were similar in repeated experiments (Figs. 2 and 3) . We observed that RNA from patients 1 1 and 12 gave larger amounts ofamplification products with the two 5' primers than with the 3' primers (Figs. 2 and 3) , while for the other patients very slight differences between the two sets ofprimers were observed. This could be related to the presence of incompletely transcribed mRNA. To demonstrate that the two amplification products in 5' and 3' were located on the same RNA, large fragments ofthe Epo mRNA (451 bp and 523 bp) were amplified from samples prepared from patients 4 and 13. These two large fragments included almost the entire coding region for the Epo cDNA. As shown in Fig. 4 , these two fragments were present in cells from both patients, demonstrating that the two small size amplification products in 5' and 3' were derived from a fully transcribed mRNA.
A more precise quantitative analysis was performed by means of competitive PCR using the 5' set of primers as above 1 and a synthetic Epo mRNA ofa different size (28) (Fig. 5) . The amount of Epo transcripts varied from 500 per cell in patient 2 to 0.5 per cell in patient 10, i.e., the threshold ofsensitivity (five patients were analyzed, Table I ). The same quantitative study was not performed with the 3' primers. Contamination was checked for in all experiments by omitting RNA extracts from the amplification mixtures in at least one tube.
In situ hybridization. To verify that Epo transcription was related to erythroid leukemic cells and not to normal blood or marrow contaminant cells, we performed in situ hybridization experiments. Only patients 2 and 4 were investigated since cells from the former clearly synthesized Epo, while Epo transcripts were only detected by PCR in the latter.
In patient 2, almost all the blast cells were labeled by the "5S-Epo riboprobe (Figs. 6 and 7) . The rare contaminant monocytes and mature erythroid cells which were also present in the sample, did not hybridize with this probe. The number of grains per blast cell was on average fivefold higher than in the control (X phage). No hybridization occurred after pretreatment of the slides with RNase. In patient 4, the histogram of the silver grain distribution showed that only a fraction of the blast cells (-15%) displayed a number of silver grain higher than the negative control value. Chinese hamster ovary cells transfected with the Epo gene and the HepG2 cell line were used as positive controls for Epo expression. Southern blot. As blast cells from patients 2 and 9 expressed the highest amounts ofEpo transcripts, the integrity ofthe Epo gene was checked by Southern blot analysis. Using several restriction enzymes that cut outside the Epo transcription unit _r -i 1_ Figure 5 (EcoRI, HindIII, BamHI, EcoRI plus HindIII, EcoRI plus BamHI, BamHI plus HindIII) or within it (SstI, BstEII, and ScaI and SstI plus BstEII) no differences with the restriction pattern obtained with normal cells were seen (Fig. 8) (Fig. 9, a and b) . Effects of anti-Epo antibodies and Epo mRNA antisense oligomers on spontaneous growth. These experiments were carried out only with cells from patients 2 and 4 which showed two apparently different pathways of autocrine stimulation. Cells from both patients responded to exogenous Epo and thus expressed Epo receptors. Epo transcripts (Northern blot analysis) and Epo secretion were detected in patient 2, whereas Epo transcripts could only be detected using PCR and in situ hybridization in patient 4. Spontaneous cell growth was significantly inhibited (78%) by an anti-Epo polyclonal antibody in patient 2 (Table II) . This inhibition was completely reversed by the addition ofexogenous Epo to the cultures. Moreover, this antibody specifically inhibited the erythroid colony formation by normal bone marrow cells grown in the presence of Epo. In contrast, this antibody had no significant effect on the spontaneous growth of cells from patient 4 (Table II) . Other patients were not tested. As Epo autocrine stimulation could occur inside the cells, we studied the effects of two Epo mRNA antisense oligomers on autonomous growth (Table II) . Since the effects ofantisense oligonucleotides are usually related to degradation ofRNA by RNaseH, we used a PCR technique to investigate whether Epo transcription was diminished after antisense treatment. Cells from patient 2 were studied since Epo transcripts were present in large amounts and easily detectable on a low number ofcells. An identical number ofcells from this patient were incubated overnight in serum-free conditions with each one of the antisense Epo oligonucleotides and with the sense oligonucleotide as a control. Cells were recovered and a A) '0- 
Discussion
Growth factor autonomy appears to be a key phenomenon in the process of tumorigenesis. It may either be an early step in leukemic transformation leading to a proliferative advantage or a mechanism transforming factor-dependent cell lines (36) . Partial or total autonomy from exogenous Epo is frequently observed in erythroid malignancies both in animal models (18) (19) (20) and in man (10) (11) (12) In this study, we investigated 13 cases ofhuman erythroleukemia in search of an autocrine stimulation by Epo. In most patients (7/13), Epo receptors were found on the cell surface in binding experiments with 125I Epo. The number of Epo receptors was not markedly different from that of normal erythroid progenitors since it never exceeded 1,000 per cell. Thus, autonomy of the leukemic cells from growth factors was not apparently related to an overexpression of Epo receptors. We subsequently investigated the endogenous production of Epo. In only one case, Epo transcripts and protein were clearly detected by Northern blotting and radioimmunoassay, respectively. However, using PCR analysis, we found Epo transcripts in 8 cases out of 13. The number of Epo transcripts present in each cell, estimated using a competitive PCR technique, ranged from 500 to 0.5 (the latter value being the threshold of detection). It has been calculated that eight molecules of Epo were sufficient to induce proliferation and differentiation of erythroid cells (41) . Therefore, since in situ hybridization showed that a fraction ofthe blast cell expressed Epo mRNA and since each transcript can be translated into several copies, an average number of Epo transcripts as low as 0.5 per cell is compatible with an autocrine stimulation. However, the detection of Epo transcripts by PCR or in situ hybridization does not exclude the possibility that the Epo transcript is incomplete or untranslated into protein. We tried to minimize this possibility by comparing results obtained with two pairs ofprimers located in the second and third exons and in the fourth and fifth exons, respectively. Some differences were observed but, with the exception of two patients, these differences were very slight, suggesting that a complete mRNA transcript was synthesized. We tried to amplify a full-length Epo mRNA from the HepG2 cell line but we were unable to perform such an amplification. However, we succeeded in amplifying two large RNA fragments which included the two previously amplified RNA fragments and almost the entire coding region of the Epo cDNA. Two patients were selected for this study since they expressed low amounts of Epo transcripts in the quantitative study. In both cases, these two large Epo mRNA fragments were detected. Therefore, it seems very unlikely that an incomplete Epo transcription was present in these patients.
It is usually thought that only cells located in the kidney and liver synthesize Epo, but the precise cell type remains controversial (42) (43) (44) . However, some data suggest that marrow macrophages also produce Epo (45) . Using PCR, we have detected small amounts of Epo transcripts in several cell types including both normal marrow and blood cells (our unpublished data), although the significance of these findings is not known since, in most cases, the number ofEpo transcripts was at the threshold of detection. To 
